SAN DIEGO, July 10 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company announced today that it has launched PROMETHEUS IBD Serology 7, the Company’s most advanced diagnostic panel for inflammatory bowel disease. With an overall accuracy of 92%, this unprecedented diagnostic test is the most comprehensive IBD test available with proprietary markers to help physicians diagnose inflammatory bowel disease (“IBD”) and to differentiate the subtypes of Crohn’s disease and ulcerative colitis.
The PROMETHEUS IBD Serology 7 test uses seven assays, including the new proprietary marker, anti-CBir1, as compared to three assays used by most other laboratories. The anti-CBir1 marker helps identify patients with Crohn’s disease, including a unique subset of patients with Crohn’s disease not previously detected by other serologic markers.
In addition to the new marker, PROMETHEUS IBD Serology 7 goes beyond other laboratory tests by using a Smart Diagnostic Algorithm (“SDA”) to calculate the serologic test results. The SDA technology derives meaning from complicated data by extracting patterns and detecting trends that are generally too complex to be detected by other statistical means.
“The combination of the new anti-CBir1 marker and SDA technology is an exciting advance in the field of IBD diagnostic testing and can provide valuable information to clinicians who use this test as part of their diagnostic workup,” said Dr. William Sandborn, Professor of Medicine at the Mayo Clinic College of Medicine.
“Most serology tests require a trade-off between sensitivity and specificity. PROMETHEUS IBD Serology 7 is unprecedented in that it has over 90% sensitivity and specificity for IBD patients in one test,” stated Dr. Bruce Neri, Prometheus’ Vice President, Diagnostic Research & Development. “To gain these levels of performance, we revolutionized our approach, not only by adding a new marker, but also by analyzing the data with a new pattern recognition algorithm. The result is the first test of its kind.”
Prometheus is a leader in the field of IBD diagnostics and has been at the forefront in offering unique, proprietary testing of serological markers with high levels of accuracy and clinical value since 1996. PROMETHEUS IBD Serology 7 is state of the art technology and the first commercially available IBD test that employs SDA technology to analyze markers of disease. The SDA pattern recognition algorithm adds analytical power and increases the accuracy of the new test compared to previous serologic tests, adding confidence to treatment decisions.
IBD Serology Background
Gastroenterologists are often faced with patients that require multiple diagnostic procedures to accurately diagnose their exact disease. Serological testing is one of the procedures that physicians use to help with diagnosis. Serological testing involves taking a small sample of a patient’s blood and analyzing it for disease markers that are specific for one disease or another, such as for Crohn’s disease or ulcerative colitis. Physicians seek diagnostic tests that are highly accurate and thus provide the best information possible to aid in making an appropriate choice of therapy for each patient.
About Prometheus
Prometheus is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. Prometheus focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus’ strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary, high-value diagnostic testing services. By integrating therapeutics and diagnostic services, Prometheus addresses the continuum of patient care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus’ corporate offices are located in San Diego, California. Additional information about Prometheus can be found at www.prometheuslabs.com.
This press release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Prometheus cautions that any forward-looking information is not a guarantee of future performance. The Company may not achieve anticipated revenue growth or maintain market acceptance of its products, or acquire, license or develop any other products for a variety of reasons. It is difficult to predict the impact of competitive products and pricing and new product development and launch. There can be no assurance that the Company can successfully commercialize, penetrate or grow the market for its products.
Prometheus Laboratories Inc.
CONTACT: Beth Kriegel, Senior Director, Finance and Investor Relations ofPrometheus Laboratories Inc., +1-858-410-2516
Web site: http://www.prometheuslabs.com/
